🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseMASH biomarker panel — OWLiver, NIS4, ELF vs biopsy correlation Page 2

MASH biomarker panel — OWLiver, NIS4, ELF vs biopsy correlation

MASHdoc_SA Tue, Mar 3, 2026 at 1:42 AM 7 replies 314 viewsPage 2 of 2
NicoleRaleigh
Member
356
1,567
Aug 2024
Raleigh, NC
Mar 3, 2026 at 4:32 AM#6
I have a question for the docs here. I was diagnosed with NAFLD (just steatosis, no confirmed NASH) about 2 years ago. My PCP has been tracking my ALT which hovers around 55-65 U/L. FibroScan showed CAP 312 but stiffness was only 5.8 kPa (F0-F1). My PCP says I don't need treatment because my fibrosis score is low. He told me to lose weight and come back in a year. But I'm worried about progression. I'm 39, BMI 34, pre-diabetic (HbA1c 5.9%). Am I wrong to want more aggressive treatment? The "lose weight" advice isn't helpful when I've been trying to do exactly that for 15 years.
15 14InsuranceTom, WendyG_ATL, SaraMom3 and 12 others
Reply Quote Save Share Report
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Mar 3, 2026 at 4:49 AM#7
You're not wrong, and this is a systemic problem in how we manage early-stage fatty liver disease. Your numbers tell a story: CAP 312 (moderate-severe steatosis), persistently elevated ALT (55-65), pre-diabetic, BMI 34, age 39. You don't have significant fibrosis YET, but you have all the risk factors for rapid progression. Your FIB-4 score (which uses age, AST, ALT, and platelet count) is probably low because you're young. FIB-4 is biased toward older patients — it systematically underestimates fibrosis risk in people under 45. What I'd recommend: 1. Ask for a hepatology referral. PCPs often don't appreciate the progression risk in young patients with metabolic NAFLD. 2. A GLP-1 RA is justified based on your pre-diabetes and obesity alone (cardiovascular risk reduction), and the liver benefit is a major bonus. 3. Get a comprehensive metabolic panel including insulin level, HOMA-IR calculation, lipid panel, and uric acid. 4. Repeat FibroScan in 6-12 months to establish a trajectory. The patients who progress fastest from F0 to F3 are exactly your phenotype — young, metabolically unhealthy, persistently elevated ALT. Intervening now while you have no fibrosis is enormously easier than trying to reverse F3 later. "Lose weight" is a treatment goal, not a treatment plan. You deserve a plan.
16 1PedsEndoPhilly, SleepDoc_PDX, RegAffairsDC and 13 others
Reply Quote Save Share Report
TinaHashiRN
Member
345
1,567
Sep 2024
Raleigh, NC
Mar 3, 2026 at 5:06 AM#8
— I was you 3 years ago. My PCP told me the same thing. "Fatty liver, lose weight, see you next year." My ALT was in the 60s, just like yours. By the time I finally got to a hepatologist, I was at F3. The thing nobody tells you is that fatty liver can progress silently. You don't feel fibrosis developing. There's no pain, no symptoms. You just go about your life and then one day someone does a FibroScan and you're at F3 wondering how you got there. Push for the hepatology referral. Push for pharmacotherapy. I wish I had pushed harder 3 years ago instead of accepting "lose weight" as a treatment plan. I might have caught this at F1 instead of F3.
26 19Dr.Martinez, mike_mod, SarahChen_PharmD and 23 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides
nick_SD_fit
Member
278
1,234
Sep 2024
San Diego, CA
Mar 3, 2026 at 5:23 AM#9
One more thing I want to add to this thread — for anyone tracking their FibroScan numbers at home, here are the general thresholds we use at our practice: Liver Stiffness (kPa): - < 7.0: F0-F1 (no significant fibrosis) - 7.0-9.5: F2 (moderate fibrosis) - 9.5-12.5: F3 (advanced fibrosis) - > 12.5: F4 (cirrhosis) CAP Score (dB/m): - < 238: S0 (no significant steatosis) - 238-260: S1 (mild steatosis) - 260-290: S2 (moderate steatosis) - > 290: S3 (severe steatosis) These cutoffs vary slightly between centers and FibroScan models, but they're a good general reference. Important caveats: FibroScan can overestimate stiffness if done within 2 hours of eating, if you have active hepatic inflammation (high ALT), or if you have significant ascites. Always fast for at least 2 hours before a FibroScan. Also — a single FibroScan is a snapshot. The trend over multiple readings is far more informative than any single number. That's why's serial measurements tell such a powerful story.
Last edited: Mar 3, 2026 at 7:23 AM
40 6PharmacoVig_BOS, SurmountFan_IN, PeptideChemSF and 37 others
Reply Quote Save Share Report
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Mar 3, 2026 at 5:40 AM#10
Thank you for all the guidance in this thread. I just want to confirm — at my 3-month mark on tirzepatide, should I request a repeat FibroScan, or is 6 months a better interval? Also, does anyone know if there's a meaningful difference between tirzepatide and semaglutide for MASH specifically? My GI chose tirz because of the GIP component, but I've seen people getting great results on sema too (like OP).
19 15KristenIndy, MarkLI_maint, Dr.PeteFamMed and 16 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register